OPV Pharmaceutical Joint Stock Company
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
OPV Pharmaceutical Joint Stock Company - overview
Established
1950
Location
Bien Hoa, -, Vietnam
Primary Industry
Pharmaceuticals
About
Based in Vietnam, OPV Pharmaceutical Joint Stock Company focuses on the development and manufacturing of a diverse range of pharmaceutical products, addressing healthcare needs in both domestic and international markets. OPV Pharmaceutical Joint Stock Company, founded in 1950 and headquartered in Bien Hoa, Vietnam, specializes in pharmaceutical product development. Recently, the company received a Growth funding round of USD 24. 8 mn from Navis Capital Partners in September 2012, bringing the total amount raised to USD 24.
8 mn. OPV Pharmaceutical Joint Stock Company manufactures a variety of pharmaceutical products, including over-the-counter (OTC) and prescription medications. The company provides solutions to hospitals, pharmacies, and healthcare providers, ensuring that patients receive effective treatment. Their commitment to quality control spans all production stages, ensuring the safety and efficacy of their medicines.
In 2023, OPV Pharmaceutical Joint Stock Company generated revenue of USD 3,872,740. 50, with an EBITDA of USD 178,531. The company's revenue model is primarily B2B, supplying healthcare institutions with pharmaceutical products, and they likely engage in partnerships with distributors for effective product logistics. The recent funding from Navis Capital Partners will enable OPV Pharmaceutical Joint Stock Company to pursue new initiatives aimed at enhancing healthcare quality in Vietnam.
The company plans to expand its product offerings and explore new geographical markets to better service regional healthcare demands.
Current Investors
Navis Capital Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.opv.vn
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
OPV Pharmaceutical Joint Stock Company - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 288,326,957,742 | 308,672,149,157 | 280,614,673,215 | 202,974,902,882 | - | - | - |
| % Revenue Growth (YoY) | - | 7.1% | (9.1%) | (27.7%) | - | - | - |
| EBITDA (USD) | (42,606,981,521) | (6,750,799,443) | (12,631,144,962) | (42,825,033,186) | - | - | - |
| Operating Income (USD) | (52,677,072,360) | (18,100,857,346) | (23,271,855,671) | (53,061,391,729) | - | - | - |
| Operating Margin | (18.3%) | (5.9%) | (8.3%) | (26.1%) | - | - | - |
| % EBITDA Margin | (14.8%) | (2.2%) | (4.5%) | (21.1%) | - | - | - |
| NET Income (USD) | (55,588,703,511) | (15,501,455,143) | (30,710,298,578) | (65,800,820,184) | - | - | - |
| % Net Margin | (19.3%) | (5.0%) | (10.9%) | (32.4%) | - | - | - |
OPV Pharmaceutical Joint Stock Company - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | OPV Pharmaceutical Joint Stock Company | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.